Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background and Objectives
A previously published study of antiretroviral pharmacokinetics in the female genital tract of HIV-infected women demonstrated differing degrees of female genital tract penetration among antiretrovirals. These blood plasma (BP) and cervicovaginal fluid (CVF) data were co-modelled for four antiretrovirals with varying CVF exposures.
Six paired BP and CVF samples were collected over 24 h, and antiretroviral concentrations determined using validated liquid chromatography (LC) with UV detection or LC-mass spectrometry analytical methods. For each antiretroviral, a BP model was fit using Bayesian estimation (ADAPT5), followed by addition of a CVF model. The final model was chosen based on graphical and statistical output, and then non-linear mixed-effects modelling using S-ADAPT was performed. Population mean parameters and their variability are reported. Model-predicated area under the concentration–time curve during the dosing interval (AUCτ) and exposure ratios of CVF AUCτ:BP AUCτ were calculated for each drug.
The base model uses first-order absorption with a lag time, a two-compartment model, and a series of transit compartments that transfer the drug from BP to CVF. Protein-unbound drug transfers into CVF for efavirenz and atazanavir; total drug transfers for lamivudine and tenofovir. CVF follows a one-compartment model for efavirenz and atazanavir, and a two-compartment model for lamivudine and tenofovir. As expected, inter-individual variability was high. Model-predicted CVF AUCτ:BP AUCτ ratios are consistent with published results.
This is the first pharmacokinetic modelling of antiretroviral disposition in BP and CVF. These models will be further refined with tissue data, and used in clinical trials simulations to inform future studies of HIV pre-exposure prophylaxis in women.
- Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505. CrossRef
- Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921–9. CrossRef
- Eron JJ Jr, Smeaton LM, Fiscus SA, Gulick RM, Currier JS, Lennox JL, et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS Clinical Trials Group Protocol 850). J Infect Dis. 2000;181:1622–8. CrossRef
- Cu-Uvin S, Caliendo AM, Reinert S, Chang A, Juliano-Remollino C, Flanigan TP, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14:415–21. CrossRef
- Launay O, Tod M, Tschöpe I, Si-Mohamed A, Bélarbi L, Charpentier C, et al. Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study. Antivir Ther. 2011;16:843–52. CrossRef
- Mitchell C, Hitti J, Paul K, Agnew K, Cohn SE, Luque AE, et al. Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retroviruses. 2011;27:35–9. CrossRef
- Henning TR, Kissinger P, Lacour N, Meyaski-Schluter M, Clark R, Amedee AM. Elevated cervical white blood cell infiltrate is associated with genital HIV detection in a longitudinal cohort of antiretroviral therapy-adherent women. J Infect Dis. 2010;202:1543–52. CrossRef
- Lorello G, la Porte C, Pilon R, Zhang G, Karnauchow T, MacPherson P. Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma. HIV Med. 2009;10:548–54. CrossRef
- Kovacs A, Wasserman SS, Burns D, Wright DJ, Cohn J, Landay A, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001;358:1593. CrossRef
- Si-Mohamed A, Kazatchkine MD, Heard I, Goujon C, Prazuck T, Aymard G, et al. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis. 2000;182:112–22. CrossRef
- Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16:1149–67. CrossRef
- Nicol MR, Kashuba ADM. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther. 2010;88:598–609. CrossRef
- Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007;21:1899–907. CrossRef
- Bristol-Myers Squibb Company. Sustiva (efavirenz) full U.S. prescribing information. Princeton: Bristol-Myers Squibb Company; 2009.
- Bristol-Myers Squibb Company. Reyataz (atazanavir) full U.S. prescribing information. Princeton: Bristol-Myers Squibb Company; 2009.
- Gilead Sciences. Viread full U.S. prescribing information. Foster City: Gilead Sciences; 2012.
- ViiV Healthcase/GlaxoSmithKline. Epivir full U.S. prescribing information. Research Triangle Park: ViiV Healthcase/GlaxoSmithKline; 2011.
- Jung BH, Rezk NL, Bridges AS, Corbett AH, Kashuba ADM. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography–tandem mass spectrometry. Biomed Chromatogr. 2007;21:1095–104. CrossRef
- Rezk NL, Crutchley RD, Kashuba ADM. Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. J Chromatogr B Anal Technol Biomed Life Sci. 2005;822:201–8. CrossRef
- Rezk NL, Tidwell RR, Kashuba ADM. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Anal Technol Biomed Life Sci. 2003;791:137–47. CrossRef
- Rezk NL, Tidwell RR, Kashuba ADM. High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2004;805:241–7. CrossRef
- Rezk NLMS, Crutchley RD, Yeh RFP, Kashuba ADMP. Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther Drug Monit. 2006;28:517–25. CrossRef
- D’Argenio DZ, Schumitzky A, Wang X. ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource; 2009.
- D’Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979;9:115–34. CrossRef
- Beijnen JH, Huitema ADR, Kappelhoff BS, Meenhorst PL, Mulder JW, Prins JM, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet. 2005;44:849–61. CrossRef
- Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006;50:3801–8. CrossRef
- Jullien V, Tréluyer J-M, Rey E, Jaffray P, Krivine A, Moachon L, et al. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother. 2005;49:3361–6. CrossRef
- Moore KHP, Yuen GJ, Hussey EK, Pakes GE, Eron JJ, Bartlett JA. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother. 1999;43:3025–9.
- Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716–23. CrossRef
- Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481–504. CrossRef
- Bulitta J, Bingölbali A, Shin B, Landersdorfer C. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J. 2011;13:201–11. CrossRef
- Bulitta J, Landersdorfer C. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J. 2011;13:212–26. CrossRef
- Okusanya OO, Hamel J, Rubino CM. SADAPTPlot—an easy-to-use R package for S-ADAPT population analysis post-processing [poster]. American Conference on Pharmacometrics; 2011 Apr 4–7; San Diego.
- Gagnieu M-C, Barkil ME, Livrozet J-M, Cotte L, Miailhes P, Boibieux A, et al. Population pharmacokinetics of tenofovir in AIDS patients. J Clin Pharmacol. 2008;48:1282–8. CrossRef
- Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3:112re4. CrossRef
- Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:437–43. CrossRef
- Salas Herrera IG, Pearson RM, Turner P. Quantitation of albumin and alpha-1-acid glycoprotein in human cervical mucus. Hum Exp Toxicol. 1991;10:137–9. CrossRef
- Dumond JBP, Patterson KBMD, Pecha ALP, Werner REBS, Andrews EP, Damle BP, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr. 2009;51:546–53. CrossRef
- Bonnet B, Diquet B, Duval X, Goujard C, Katlama C, Legrand M, et al. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy. Clin Pharmacokinet. 2005;44:1267–78. CrossRef
- Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J Jr, Gallant JE, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 2006;42:1189–96. CrossRef
- Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother. 2009;53:2346–53. CrossRef
- Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women
Volume 51, Issue 12 , pp 809-822
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing AG
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 3320 Kerr Hall, CB 7569, Chapel Hill, NC, 27599-7569, USA
- 2. School of Pharmacy and Pharmaceutical Sciences, State University of New York, University at Buffalo, Buffalo, NY, USA
- 3. School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA